http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006100265-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a3a23a8a6301923fa3f8aff70a785e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e708c04553b412eaf7415867aca15f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3bea6f097fffce4ae4aa9f31c117831e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa15c64dbdc3842094f961f7a8b931f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e439513a1258494424f93e8a93c01ecb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 |
| filingDate | 2002-12-20^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4c07e790a2f5598b7b40a31e24a05b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01f6e9bed22951ad9efc9231e9ca2ed9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93ba224c9f6ebd6bcc9db99229e96ff0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8db0840446828a74d3d4d43d956846e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab9c8899fc1a87847bf2d6bd7a50665e |
| publicationDate | 2006-05-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2006100265-A1 |
| titleOfInvention | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents |
| abstract | This invention pertains to certain 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds, and analogs thereof, including compounds of the following formula, which are, inter alia, antiproliferative agents, anticancer agents, and/or thioredoxin/thioredoxin reductase inhibitors: formula (I) wherein: Ar is a 1-(sulfonyl)-1H-indol-2-yl group; the bond marked α is independently: (a) a single bond; or: (b) a double bond; the bond marked β is independently: (a) a single bond; or: (b) a double bond; the group —OR O is independently: (a) —OH; (b) an ether group (e.g., —OMe); or: (c) an acyloxy (i.e., reverse ester) group (e.g., —OC(═O)Me); each of R 2 , R 3 , R 5 , and R 6 , is independently a ring substituent and is: (a) H; (b) a monovalent monodentate substituent; or: (c) a ring substituent which, together with an adjacent ring substituent, and together with the ring atoms to which these ring substituents are attached, form a fused ring; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), and/or conditions mediated by thioredoxin/thioredoxin reductase. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023133507-A1 |
| priorityDate | 2002-12-20^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1339.
| Next Page | Last Page |